Keywords: obstructive sleep apnea, anti-obesity medications, obesity, tirzepatide, semaglutide Introduction Obstructive sleep apnea and obesity are two interrelated health conditions that have become increasingly prevalent worldwide, posing significant public health challenges
Several factors may explain a drop in sex drive while taking GLP-1 medications: Caloric deficit and fatigue: Eating significantly less can leave you tired, which directly reduces interest in sex
Studies that look into DSIPs effects on opioid pathways show it involves complicated processes, not just connecting to receptors
Postprandial plasma GLP-1 levels are elevated in individuals with postprandial hypoglycaemia following Roux-en-Y gastric bypassa systematic review
The legal framework for compounding non-approved drugs is unclear
Stalled weight loss can easily be attributed to low amounts of calories burned through scant physical activity, whether youre on semaglutide or not